Indeed, pharmacotherapy with GLP-1 receptor or dual GIP/GLP-1 receptor agonists in patients with obesity achieves impressive reductions in body weight in the range of 15–25% compared with TRE or other nutritional interventions, which are typically in the range of 3–4% (1, 61). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.